Stereotactic radiation therapy for treatment of canine intracranial meningiomas

Griffin, Lynn; Nolan, Michael W.; Selmic, Laura E.; Randall, Elissa; Custis, J. T.; LaRue, Susan M.

doi:10.1111/vco.12129

Cited by 52 publications

(99 citation statements)

References 47 publications

(66 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The dose‐limiting normal tissue in our study was the normal brain. The goal of the Radiation Oncology Service at CSU is to keep 1.1 cc of normal brain under 24Gy for 3 fractions and under 27Gy for 4 fractions . Assuring that the brain was within tolerance constraints took precedence over total radiation dosage administered to the tumor volumes.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Stereotactic radiation therapy for the treatment of functional pituitary adenomas associated with feline acromegaly

Wormhoudt

Boss

Lunn

et al. 2018

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundConventional fractionated radiotherapy has been shown to be partially effective for management of pituitary tumors in cats that cause acromegaly and diabetes mellitus (DM), but, the efficacy and safety of stereotactic radiation therapy (SRT) as a treatment for acromegalic cats has not been described.HypothesisStereotactic radiation therapy is an effective and safe treatment for controlling acromegaly associated with pituitary adenomas in cats. Additionally, SRT‐treated acromegalic cats with DM will experience a decrease in insulin requirements after radiation therapy.AnimalsFifty‐three client‐owned cats referred to Colorado State University for SRT to treat pituitary tumors causing poorly controlled DM secondary to acromegaly.MethodsRetrospective study of cats treated for acromegaly with SRT between 2008 and 2016 at Colorado State University. Diagnosis of acromegaly was based on history, physical examination, laboratory results, and cross‐sectional imaging of the pituitary. Signalment, radiation protocol, insulin requirements over time, adverse effects, and survival were recorded.ResultsMedian survival time was 1072 days. Of the 41 cats for which insulin dosage information was available, 95% (39/41) experienced a decrease in required insulin dose, with 32% (13/41) achieving diabetic remission. Remission was permanent in 62% (8/13) and temporary in 38% (5/13) cats. Median duration to lowest insulin dose was 9.5 months. Of the treated cats, 14% developed hypothyroidism and required supplementation after SRT.ConclusionsStereotactic radiation therapy is safe and effective for treating cats with acromegaly. Cats treated with SRT have improved survival time and control of their DM when compared to previously reported patients treated with non‐SRT.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Stereotactic radiation therapy is now an accepted treatment for many tumor types and locations in both human and veterinary medicine . Stereotactic radiation therapy delivers an ablative dose of radiation to the tumor while avoiding normal tissues in the field .…”

Section: Introductionmentioning

confidence: 99%

Stereotactic radiation therapy for the treatment of functional pituitary adenomas associated with feline acromegaly

Wormhoudt

Boss

Lunn

et al. 2018

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…The efficacies of various treatment modalities on canine brain tumours have been previously reported, including surgery, radiotherapy (RT) and cytotoxic chemotherapy . Traditionally, RT with or without surgery has been the mainstay treatment for most intracranial neoplasia .…”

Section: Introductionmentioning

confidence: 99%

Survival times in dogs with presumptive intracranial gliomas treated with oral lomustine: A comparative retrospective study (2008‐2017)

Moirano

Dewey

Wright

et al. 2018

Vet Comparative Oncology

View full text Add to dashboard Cite

Intracranial gliomas are a common malignancy in dogs, and are associated with a poor prognosis due to their aggressive nature and a lack of clinically effective treatments. The efficacies of various treatment modalities for canine brain tumours have been previously described, though little data exist on the use of cytotoxic chemotherapy. A comparative retrospective study, including 40 cases from 5 northeastern US veterinary hospitals, from 2008 to 2017, was conducted. Variables analysed in this study with relation to overall survival and prognostic significance included: age, sex, clinical signs, clinical sign duration, tumour location and treatment protocol used. Dogs with presumptive intracranial gliomas treated with lomustine chemotherapy lived longer (median, 138 days) than those treated exclusively with symptomatic care (median, 35 days; P = .0026 log-rank, 0.0138 Wilcoxon). Additionally, a duration of clinical signs ≥16 days prior to diagnosis (median, 109 days) was associated with a longer survival than a duration <16 days prior (median, 25 days; P = .0100 log-rank, 0.0322 Wilcoxon). Lomustine-associated side effects included neutropenia in 46% of dogs, anaemia in 15% and thrombocytopenia in 15%. Potential renal and hepatotoxicity based on increased BUN and/or creatinine and ALT values were reported in 15% and 50% of dogs, respectively. This study provides evidence that lomustine therapy may be effective in prolonging survival in dogs with intracranial gliomas and should be considered as a potential treatment option. Although lomustine-related toxicities are fairly common, they are rarely life threatening and often do not result in discontinuation of therapy.

show abstract

“…Radiation therapy has become a mainstay of treatment for intracranial neoplasia in both human and veterinary patients, either as a primary or adjunctive treatment (Dickinson, 2014). Radiotherapy has demonstrated to improve ST in presumptive and confirmed meningiomas, with ST ranging from 240 to 577 days (Turrel et al, 1984;Evans et al, 1993;Axlund et al, 2002;Bley et al, 2005;Griffin et al, 2014;Rossmeisl, 2014). Radiation therapy has been reported to be beneficial when compared to SRA for the treatment of meningiomas (Axlund et al, 2002).…”

Section: Introductionmentioning

confidence: 99%

Long-term follow-up of surgical resection alone for primary intracranial rostrotentorial tumors in dogs: 29 cases (2002-2013)

Suñol¹,

Mascort²,

Font³

et al. 2018

Open Vet J.

View full text Add to dashboard Cite

Intracranial neoplasia is frequently encountered in dogs. After a presumptive diagnosis of intracranial neoplasia is established based on history, clinical signs and advanced imaging characteristics, the decision to treat and which treatment to choose must be considered. The objective of this study is to report survival times (ST) for dogs with intracranial meningiomas and gliomas treated with surgical resection alone (SRA), to identify potential prognostic factors affecting survival, and to compare the results with the available literature. Medical records of 29 dogs with histopathologic confirmation of intracranial meningiomas and gliomas treated with SRA were retrospectively reviewed. For each dog, signalment, clinical signs, imaging findings, type of surgery, treatment, histological evaluation, and ST were obtained. Twenty-nine dogs with a histological diagnosis who survived >7 days after surgery were included. There were 15 (52%) meningiomas and 14 (48%) gliomas. All tumors had a rostrotentorial location. At the time of the statistical analysis, only two dogs were alive. Median ST for meningiomas was 422 days (mean, 731 days; range, 10-2735 days). Median ST for gliomas was 66 days (mean, 117 days; range, 10-730 days). KaplanMeier analysis indicated that ST was significantly longer for meningiomas than for gliomas (P<0.05). A negative correlation between the presence of a midline shift and ST (P=0.037) and ventricular compression and ST (P=0.038) was observed for meningiomas. For gliomas, there were no significant associations between ST and any of the variables evaluated. In conclusion, the results of this study suggest that, for dogs that survived >7 days postoperatively, SRA might be an appropriate treatment, particularly for meningiomas, when radiation therapy is not readily available. Also, the presence of midline shift and ventricular compression might be negative prognostic factors for dogs with meningiomas.

show abstract

Stereotactic radiation therapy for treatment of canine intracranial meningiomas

Cited by 52 publications

References 47 publications

Stereotactic radiation therapy for the treatment of functional pituitary adenomas associated with feline acromegaly

Stereotactic radiation therapy for the treatment of functional pituitary adenomas associated with feline acromegaly

Survival times in dogs with presumptive intracranial gliomas treated with oral lomustine: A comparative retrospective study (2008‐2017)

Long-term follow-up of surgical resection alone for primary intracranial rostrotentorial tumors in dogs: 29 cases (2002-2013)

Contact Info

Product

Resources

About